AB Science Competitors and Similar CompaniesClear all
AB Science's competitors and similar companies include Biogen, Chiesi Group, UCB and Cadila Pharmaceuticals.
 AB Science AB Science is a pharmaceutical company that engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. |  Chiesi Group Chiesi Group (Gruppo Chiesi, also known as CHIESI Farmaceutici) is a company that researches, develops, produces, and commercializes therapeutic solutions. |  UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. |  Cadila Pharmaceuticals Cadila Pharmaceuticals is a company that develops and manufactures medicines for patients. | |
Founding Date | Founding Date 2001 | Founding Date 1978 | Founding Date 1935 | Founding Date 1928 | Founding Date 1951 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Private |
Tags | |||||
Locations | Locations Paris, FR HQ | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | Locations Parma, IT HQ Melbourne, AU Wien, AT Machelen, BE Santana De Parnaíba, BR São Paulo, BR Sofia, BG see more | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more | |
Employees | Employees 40 | Employees 7,605 | Employees 5,8541% increase | Employees 9,052 | Employees 8,5201% increase |
Valuation ($) | Valuation ($) 70.2 m | Valuation ($) 26.7 b | Valuation ($) N/A | Valuation ($) 34.3 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) €1.1m (FY, 2024) | Revenue (est.) $9.9b (FY, 2025) | Revenue (est.) €2.4b (Y, 2021) | Revenue (est.) €7.4b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods (€176k) (FY, 2024) | Cost of goods $2.4b (FY, 2025) | Cost of goods N/A | Cost of goods €1.4b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit €1.2m (FY, 2024) | Gross profit $7.5b (FY, 2025) | Gross profit N/A | Gross profit €7.2b (FY, 2025) | Gross profit N/A |
Net income | Net income (€7.8m) (FY, 2024) | Net income $1.3b (FY, 2025) | Net income N/A | Net income €1.6b (FY, 2025) | Net income N/A |
For sources of this data, please see the company profile
View Company Profiles
Biogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View companyChiesi Group
HQ
Parma, IT
Chiesi Group (Gruppo Chiesi, also known as CHIESI Farmaceutici) is a company that researches, develops, produces, and commercializes therapeutic solutions.
View companyUCB
HQ
Brussels, BE
Employees
9,052
UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View companyCadila Pharmaceuticals
HQ
Bavla, IN
Employees
8,520↑ 1% increase
Cadila Pharmaceuticals is a company that develops and manufactures medicines for patients.
View company